98%
921
2 minutes
20
Hypertrophic scars and keloids are the results of an exaggerated healing process and are often associated with significant patient morbidity. Fractional ablative lasers create microchannels in the skin and penetrate into the substance of the scar, inducing a normal healing response in zones of created damage. Focal delivery of scar-modulating agents into the scar through these microchannels-a process termed laser-assisted drug delivery (LADD)-is a promising and developing treatment modality. In this systematic review, we aim to critically examine the evidence of LADD in the treatment of hypertrophic scars and keloids. The evidence suggests that LADD improves outcomes in hypertrophic scars and keloids. LADD is a more effective treatment modality than the topical application of agents in hypertrophic scars and equally effective as the intralesional injection of agents in keloids. There were few reports of adverse events. Evidence supports the use of LADD as an adjunct to non-surgical measures or a treatment modality to be used before more invasive measures such as surgical excision. However, the quality of evidence supporting this conclusion is inconsistent and lacks power. Additional studies are required to optimize dosages, laser settings, and agent choices for the treatment of these lesions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jbcr/irae023 | DOI Listing |
Int J Womens Dermatol
October 2025
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Background: Few studies have comprehensively assessed dermatologic conditions in women, particularly among different racial and ethnic groups.
Objective: This study characterizes common dermatologic diagnoses in adult women (acne), emphasizing conditions disproportionately affecting women of color (WOC) (hidradenitis suppurativa [HS], hypertrophic scars, and scarring and nonscarring alopecia).
Methods: This retrospective cohort study analyzed data from Northwestern Medicine's Enterprise Data Warehouse, covering 637,124 patient visits from 2018 to 2021.
Front Oncol
August 2025
Institute of Burns, Tongren Hospital of Wuhan University and Wuhan Third Hospital, Wuhan, China.
Introduction: Facial scars are generally disfiguring and can cause both physiological and psychological trauma. Currently, there is a lack of effective treatment options for facial scars. In recent years, local superficial radiation therapy has emerged as a clinically proven treatment to effectively prevent scar recurrence after surgery.
View Article and Find Full Text PDFOpen Med (Wars)
August 2025
Department of Burns and Wound Repair, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Objective: Hypertrophic scars (HS) are a fibrotic proliferative disorder that results from an abnormal wound healing process, presenting significant challenges for clinical intervention. The primary characteristics of HS include excessive collagen deposition and angiogenesis. In recent years, the study of mesenchymal stem cells (MSCs) and their derived exosomes has emerged as a prominent area of research within the academic community.
View Article and Find Full Text PDFAnn Plast Surg
September 2025
From the Department of Plastic Surgery, Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville, TN.
Hypertrophic scarring (HTS) remains a critical challenge in burn care, often resulting in debilitating contractures, chronic pain, and significant psychosocial burden. While current treatment emphasizes structural repair, recent advances underscore the importance of addressing the biological drivers of fibrosis. This review synthesizes evolving strategies in burn scar prevention, highlighting tissue-engineered matrices, autologous cell therapies, and predictive molecular tools that shift care from reactive to regenerative.
View Article and Find Full Text PDFMol Med Rep
November 2025
Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Aberrant extracellular matrix (ECM) production by dermal fibroblasts drives fibrotic skin diseases, which has an adverse impact on the lives of patients. Current treatments are limited; therefore, the development of new antifibrotic strategies is necessary. The aim of the present study was to investigate zinc finger 469 (ZNF469) as a potential ECM regulator in skin fibrosis.
View Article and Find Full Text PDF